“…NTRK gene fusions are emerging biomarkers and their use in translational research and also for patients’ stratification is at its beginning. Particularly, NTRK1-3 fusions with other genes were recently studied in several solid tumors harboring this signature as predictors of prognosis ( Table 2 ) [ [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] ]. In thyroid carcinomas, a cohort of 259 patients assessed NTRK chromosomal rearrangements and their correlation with histological patterns [ 39 ].…”